Dx dialogues: identifying patients with cutaneous melanoma for TIL therapy
Dx dialogues: HLA typing and patient selection with cutaneous melanoma
Dx dialogues: how precision medicine is changing the AD landscape
Dx dialogues: a potential paradigm shift in the treatment of metastatic breast cancer
Dx dialogues: how AI might be implemented in the diagnosis and care of metastatic breast cancer
Dx dialogues: changes in treatment sequencing for metastatic breast cancer
Dx dialogues: versatile treatment options across the multiple myeloma landscape
Dx dialogues: the future of personalized ovarian response prediction
Dx dialogues: why staying current with technology is critical in oncology
Dx dialogues: advancements in treating indolent systemic mastocytosis
Desmoid tumors are noncancerous and do not metastasize, but they can invade nearby tissues and structures.
Many patients with non-Hodgkin’s lymphoma choose to seek a second opinion. Here are a few questions to ask to help make the decision.
These strategies can help you stay comfortable and productive during the work day.
A look at what information to record and some of the key benefits.
Although it’s not the most common cancer, it is among the most deadly. Here’s why—and why there’s hope for future treatments.